Out-of-Pocket Costs for Insulin Among People with Medicare Decreased by Half Between 2020 and 2024 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Medicare Beneficiaries’ Out-of-Pocket Insulin Costs Fell by 50% From 2020 to 2024

  • By

  • Juliette Cubanski

  • Meredith Freed

  • Anthony Damico

  • November 20, 2026

Share

  • 1

    Among Medicare Part D insulin users without low-income subsidies, aggregate out-of-pocket spending fell from $971 million in 2020 to $506 million in 2024.

  • 2

    Out-of-pocket spending per insulin prescription among these enrollees decreased 54%, from $54 in 2020 to $25 in 2024.

  • 3

    The Part D Senior Savings Model began limiting copayments for selected insulin products in participating plans in 2021 and continued through 2023.

  • 4

    The Inflation Reduction Act’s mandatory $35 monthly insulin copay cap took effect in 2023 for Medicare Part D and Part B beneficiaries.

  • 5

    For the 10 most commonly used insulin products available in both years, 30-day out-of-pocket costs exceeded $35 in 2020 and were below $35 in 2024.

Original Source(s)

Related Content